WO2023121314A1 - Utilisation d'un extrait de tubercule d'apios americana pour une protection contre une lésion hépatique alcoolique ou une lésion cérébrale alcoolique - Google Patents
Utilisation d'un extrait de tubercule d'apios americana pour une protection contre une lésion hépatique alcoolique ou une lésion cérébrale alcoolique Download PDFInfo
- Publication number
- WO2023121314A1 WO2023121314A1 PCT/KR2022/020995 KR2022020995W WO2023121314A1 WO 2023121314 A1 WO2023121314 A1 WO 2023121314A1 KR 2022020995 W KR2022020995 W KR 2022020995W WO 2023121314 A1 WO2023121314 A1 WO 2023121314A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alcoholic
- extract
- disease
- liver
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 138
- 235000003276 Apios tuberosa Nutrition 0.000 title claims abstract description 111
- 208000022309 Alcoholic Liver disease Diseases 0.000 title claims abstract description 74
- 206010001596 Alcohol induced persisting dementia Diseases 0.000 title claims abstract description 26
- 241001098044 Apios americana Species 0.000 title claims abstract 15
- 239000000203 mixture Substances 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 57
- 206010019133 Hangover Diseases 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 210000004556 brain Anatomy 0.000 claims abstract description 23
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 142
- 230000001476 alcoholic effect Effects 0.000 claims description 70
- 239000003814 drug Substances 0.000 claims description 35
- 235000013376 functional food Nutrition 0.000 claims description 32
- 230000036541 health Effects 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 22
- 210000005228 liver tissue Anatomy 0.000 claims description 21
- 208000014644 Brain disease Diseases 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 claims description 17
- 208000009885 central pontine myelinolysis Diseases 0.000 claims description 17
- 208000010706 fatty liver disease Diseases 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 15
- 108010082126 Alanine transaminase Proteins 0.000 claims description 15
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 15
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 15
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 15
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 15
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 101710187578 Alcohol dehydrogenase 1 Proteins 0.000 claims description 14
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 claims description 14
- 230000006872 improvement Effects 0.000 claims description 14
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 230000001681 protective effect Effects 0.000 claims description 12
- 208000000044 Amnesia Diseases 0.000 claims description 11
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 10
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 9
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 9
- 230000008021 deposition Effects 0.000 claims description 9
- 230000004973 motor coordination Effects 0.000 claims description 9
- 230000036421 sense of balance Effects 0.000 claims description 9
- 208000007848 Alcoholism Diseases 0.000 claims description 8
- 208000031091 Amnestic disease Diseases 0.000 claims description 8
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 8
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 8
- 230000006986 amnesia Effects 0.000 claims description 8
- 208000003130 Alcoholic Neuropathy Diseases 0.000 claims description 7
- 208000028698 Cognitive impairment Diseases 0.000 claims description 7
- 206010010071 Coma Diseases 0.000 claims description 7
- 208000020701 alcoholic polyneuropathy Diseases 0.000 claims description 7
- 208000029028 brain injury Diseases 0.000 claims description 7
- 208000025434 cerebellar degeneration Diseases 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- 230000036765 blood level Effects 0.000 claims description 6
- 201000007930 alcohol dependence Diseases 0.000 claims description 5
- 239000002417 nutraceutical Substances 0.000 claims description 5
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 206010001605 Alcohol poisoning Diseases 0.000 claims description 4
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 4
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims description 4
- 241001502883 Marcia Species 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 230000006886 spatial memory Effects 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims 1
- 244000176051 Apios tuberosa Species 0.000 description 95
- 235000019441 ethanol Nutrition 0.000 description 74
- 241000913828 Apios Species 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 235000013305 food Nutrition 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000010172 mouse model Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 230000006931 brain damage Effects 0.000 description 7
- 231100000874 brain damage Toxicity 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000010825 rotarod performance test Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000010045 Wernicke encephalopathy Diseases 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 238000009227 behaviour therapy Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- -1 for example Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000019736 Cranial nerve disease Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 208000019749 Eye movement disease Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 208000028780 ocular motility disease Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010001623 Alcoholic hangover Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000005622 Gait Ataxia Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 235000018122 Helianthus giganteus Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 201000000251 Locked-in syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000001505 Musculoskeletal Abnormalities Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000775685 Orogenia linearifolia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000008921 border disease Diseases 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000030363 nerve development Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Definitions
- the present invention relates to the use of an Apios americana tuber extract for the protection of alcoholic liver damage or alcoholic brain damage, and more particularly, a composition for preventing alcoholic liver or brain damage using Apios americana tuber extract and protection against alcoholic liver or brain damage provides a way Additionally, the present invention provides a composition for preventing, improving, or treating alcoholic liver disease or brain nervous system disease using Apios americana tuber extract, and a method for preventing, improving or treating alcoholic liver disease or brain nervous system disease. Furthermore, the present invention provides a composition for relieving hangover and a method for relieving hangover using Apios americana tuber extract.
- Alcohol is the cause of many diseases, from very mild symptoms to serious diseases that can lead to death.
- the liver has detoxification and decomposition functions to detoxify drugs, toxic substances, alcohol, etc., but this detoxification function of the liver easily damages liver cells, which can cause drug-related, toxic, and alcoholic liver diseases.
- Alcoholic liver disease can be largely divided into alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis according to clinical symptoms, and usually occurs when 60-80 g of alcohol is consumed per day for about 10 years.
- Alcoholic fatty liver is caused by the accumulation of cholesterol and triglycerides in the liver cells due to excessive alcohol intake. It can be recovered soon if you stop drinking, but if you continue to drink, it develops into hepatitis.
- Alcoholic hepatitis is a state in which liver cell necrosis and inflammation occur, and it shows various symptoms such as fatigue, anorexia, weight loss, jaundice, fever, and right upper quadrant pain. About 40% of patients suffering from this develop alcoholic cirrhosis.
- Alcoholic cirrhosis is a condition that cannot be restored to a normal liver, and shows various symptoms such as general fatigue, loss of appetite, ascites, esophageal varices, hemorrhage, hepatic encephalopathy, and coma. It is known that 50% of deaths due to end-stage liver disease are caused by alcohol.
- alcohol induces morphological changes by causing loss of nerve cells by causing disorders in proliferation and differentiation of nerve cells, nerve development, and cell-to-cell interactions, and furthermore, causes cranial nerve disease due to death of nerve cells. do.
- Acetylcholinesterase inhibitors and NMDA glutamate receptor blockers are currently being used to treat alcoholic brain disease, but they only have the effect of relieving symptoms rather than treating them, and the prevention and treatment of alcoholic brain disease are not clear. Therefore, the development of drugs with decisive effects is required.
- chemotherapeutic agents developed and used for disease treatment often show side effects and toxicity due to long-term administration, so attention is focused on research to explore new treatments from natural products that can effectively treat diseases while being harmless to the human body.
- Substances separated and purified from natural substances are relatively less toxic and are safe even when consumed for a long period of time compared to pharmaceuticals, so they have recently been in the limelight as therapeutic agents and therapeutic supplements for various diseases.
- Korean Patent Publication No. 10-2018-0095193 discloses the anticancer activity of Apios americana extract
- Korean Patent Publication No. 10-2015-0132616 discloses Apios extract or fermentation It has been disclosed that the extract exhibits an immune enhancing effect by increasing the gene or protein expression of NO, an immune enhancer, in RAW 264.7 cells.
- the present inventors confirm that Apios americana Medikus tuber extract exhibits a protective effect against alcoholic liver damage and brain damage and can be used in combination for the prevention, improvement, or treatment of alcoholic liver disease and alcoholic brain disease. By confirming that it can be, the present invention was completed.
- an object of the present invention is to provide a composition for protecting alcoholic liver damage or relieving hangover using Apios americana tuber extract.
- a further object of the present invention is to provide a composition for preventing, improving or treating alcoholic liver disease.
- a further object of the present invention is to provide a method for protecting alcoholic liver damage or relieving hangover and a method for preventing, improving or treating alcoholic liver disease using Apios americana tuber extract.
- a further object of the present invention is to provide the use of Apios americana tuber extract in the preparation of a medicine or health functional food for protecting alcoholic liver damage or relieving hangover.
- a further object of the present invention is to provide the use of Apios americana tuber extract in the preparation of a medicament or health functional food for the prevention, improvement or treatment of alcoholic liver disease.
- Another object of the present invention is to provide a composition for protecting alcoholic brain damage using Apios americana tuber extract.
- a further object of the present invention is to provide a composition for preventing, improving or treating alcoholic brain disorders.
- a further object of the present invention is to provide a method for protecting alcoholic brain damage using Apios americana tuber extract and a method for preventing, improving or treating alcoholic brain disorders.
- the present invention further aims to provide the use of Apios americana tuber extract in the preparation of a medicament or health functional food for the protection of alcoholic brain damage.
- a further object of the present invention is to provide the use of Apios americana tuber extract in the preparation of a pharmaceutical or health functional food for the prevention, improvement or treatment of alcoholic brain disorders.
- the present invention provides a composition for protecting alcoholic liver damage or relieving hangover, comprising an extract of Apios Americana tuber as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating alcoholic liver disease and/or a health functional food composition for preventing or improving alcoholic liver disease comprising the above-described composition.
- the present invention provides a method for protecting alcoholic liver damage or relieving hangover and preventing, improving or preventing alcoholic liver disease, comprising administering an effective amount of Apios Americana tuber extract to a subject in need thereof. provide a treatment method.
- the present invention further provides the use of Apios Americana tuber extract in the preparation of a medicament or health functional food for protecting alcoholic liver damage or relieving hangover.
- the present invention further provides the use of Apios Americana tuber extract in the preparation of a medicament or nutraceutical for preventing, ameliorating or treating alcoholic liver disease.
- the extract may be extracted using water, C1 to C4 lower alcohol, or a mixture thereof as a solvent.
- the extract may exhibit any one or more of the following effects (a) to (d):
- the alcoholic liver disease may be any one or more selected from the group consisting of alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis.
- the composition for relieving hangover may be a health functional food composition.
- the present invention also provides a composition for protecting against alcoholic brain damage comprising Apios Americana tuber extract as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating alcoholic brain nervous system disease and/or a functional health food composition for preventing or improving alcoholic brain disease, comprising Apios Americana tuber extract as an active ingredient.
- the present invention provides a method for protecting alcoholic brain damage or preventing, improving or treating alcoholic brain disease, comprising administering an effective amount of Apios Americana tuber extract to a subject in need thereof.
- the present invention further provides the use of Apios Americana tuber extract in the manufacture of a medicament or nutraceutical for protection against alcoholic brain damage.
- the present invention further provides the use of Apios Americana tuber extract in the manufacture of a medicament or health functional food for the prevention, improvement or treatment of alcoholic brain disorders.
- the extract may be extracted using water, C1 to C4 lower alcohol, or a mixture thereof as a solvent.
- the extract may exhibit any one or more of the following effects (a) to (c):
- the alcoholic brain nervous system disease is alcohol intoxication, alcoholic amnesia, alcoholic dementia, alcoholic coma, Wernicke-Korsakoff syndrome, alcoholic neuropathy, marcia parvi - It may be any one or more selected from the group consisting of Marchiafava-Bignami disease (MBD), alcoholic cerebellar degeneration, and central pontine myelinolysis (CPM).
- MBD Marchiafava-Bignami disease
- CPM central pontine myelinolysis
- composition containing the Apios americana extract according to the present invention exhibits a protective effect against alcohol-induced liver damage and brain damage, thereby preventing, improving or treating various alcoholic diseases such as alcoholic liver disease or alcoholic brain disease. provide effect.
- it since it increases the mRNA expression of ADH1 and ALDH2 in liver tissue, it can be used as a hangover reliever.
- Figure 1 shows the change in relative weight of liver tissue according to the administration of Apios americana tuber extract in a chronic alcohol-induced fatty liver mouse model (Con: normal control group; EtOH: ethanol-administered group; AP100: Apios americana tuber extract 100 mg/kg and AP200: Apios americana tuber extract 200 mg/kg administration group, *p ⁇ 0.05, ***p ⁇ 0.001 vs ethanol administration group).
- Figure 2 shows the change in blood triglyceride concentration according to the administration of Apios americana tuber extract in a chronic alcoholic fatty liver induced mouse model (Con: normal control group; EtOH: ethanol administration group; AP100: Apios americana tuber extract 100 mg/kg and AP200: Apios americana tuber extract 200 mg/kg administration group, *p ⁇ 0.05 vs ethanol administration group).
- Figure 3 shows the changes in AST and ALT levels in blood according to the administration of Apios americana tuber extract in a chronic alcoholic fatty liver induced mouse model (Con: normal control group; EtOH: ethanol administration group; AP100: Apios americana tuber extract 100 mg / kg administration group; and AP200: Apios americana tuber extract 200 mg/kg administration group, *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001 vs ethanol administration group).
- Figure 4 shows the changes in the mRNA expression levels of ADH1 and ALDH2 in liver tissue according to the administration of Apios americana tuber extract in a mouse model induced by chronic alcoholic fatty liver (Con: normal control group; EtOH: ethanol administration group; AP100: Apios americana group) Tuber extract 100 mg/kg administration group; and AP200: Apios americana tuber extract 200 mg/kg administration group, *p ⁇ 0.05 vs ethanol administration group).
- Figure 5 is a photograph of H&E tissue staining observing the degree of fat deposition in liver tissue according to the administration of Apios americana tuber extract in a chronic alcoholic fatty liver induced mouse model (Con: normal control group; EtOH: ethanol-administered group; and AP100: Apios americana tuber extract 100 mg/kg administration group).
- Figure 6 is a schematic diagram showing the design and timeline of mouse behavioral tests to confirm the protective effect of Apios americana extract against alcoholic brain damage.
- Figure 8 shows the change in latency time to fail (latency time to fail) according to the administration of Apios americana tuber extract in the rotarod test (Con: normal control group; EtOH: ethanol administration group; AP100: Apios americana tuber extract 100 mg/kg administration group; and AP200: Apios americana tuber extract 200 mg/kg administration group, *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001 vs ethanol administration group).
- the present inventors confirmed that the tuber extract exhibits a protective effect against alcoholic liver damage and brain damage, and can be applied in combination to the prevention, improvement, or treatment of alcoholic liver disease and/or alcoholic brain disease.
- a composition with a solution to the above problems was sought.
- a first aspect of the present invention relates to the use of an Apios americana tuber extract that exhibits a protective effect against alcoholic liver damage.
- the present invention provides a composition for protecting alcoholic liver damage or relieving hangover, comprising an Apios Americana tuber extract as an active ingredient.
- Apios americana As used herein, the term "Apios americana ( Apios americana Medikus)" is a creeping perennial herb belonging to the legume family, and is also called Indian potato.
- the part of Apios americana used in the composition of the present invention is an underground tuber, and the tuber of Apios americana can be purchased commercially or collected or cultivated in nature.
- the Apios americana tubers may be dried through a conventional drying method such as natural drying or hot air drying.
- extract refers to the Apios americana tuber, more preferably an extract obtained by extracting the dried Apios americana tuber, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, It includes extracts of all formulations that can be formed using the extract itself and the extract, such as a refined product or a purified product of the extract, or a mixture thereof.
- the extract of the present invention may be extracted from natural, hybrid or mutant plants of Apios americana, and may also be extracted from plant tissue culture.
- the extract may be prepared by using hexane, chloroform, methylene chloride, ethyl acetate, acetone, C 1 to C 4 lower alcohol, water or a mixed solvent thereof as an extraction solvent, preferably It may be prepared by using C 1 to C 4 lower alcohol, water, or a mixed solvent thereof as an extraction solvent, but is not limited thereto.
- the extract may be obtained by using ethanol as an extraction solvent.
- a method for preparing the extract is not particularly limited, and may be extracted according to a method commonly used in the art.
- Non-limiting examples of the extraction method include immersion extraction, hot water extraction, ultrasonic extraction, filtration, reflux extraction, and the like, which may be performed alone or in combination of two or more methods.
- the Apios americana extract can be prepared by extracting dried tubers of Apios americana one or more times using the extraction solvent, obtained by concentrating the solvent extract under reduced pressure and then freeze-drying or spray-drying. It can be prepared as a dry extract.
- composition of the present invention may contain Apios americana tuber fraction as an active ingredient for protection against alcoholic liver damage or hangover relief.
- fraction refers to a result obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.
- the fractionation method for obtaining the fraction is not particularly limited, and may be performed according to a method commonly used in the art.
- a non-limiting example of the fractionation method is a method of obtaining a fraction from the extract by treating the extract obtained by extracting the dried Apios americana tuber with a predetermined solvent.
- the solvent used to obtain the fraction may be hexane, chloroform, methylene chloride, ethyl acetate, acetone, C 1 to C 4 lower alcohol, water, or a mixed solvent thereof, but is not limited thereto. .
- the protective effect of alcoholic liver damage according to the administration of Apios americana tuber extract was confirmed in a chronic alcoholic fatty liver induced mouse model.
- FIGS. 1 to 5 in the Apios americana tuber extract administration group, alcohol-induced fat deposition in liver tissue was suppressed (FIG. 1 and FIG. 5), and blood triglyceride concentration and AST and ALT increased by alcohol It was confirmed that the levels decreased (FIG. 2 and FIG. 3), and the mRNA expression of ADH1 and ALDH2 in liver tissue decreased due to alcohol increased (FIG. 4). From this, it can be seen that Apios americana tuber extract protects the liver from liver damage caused by chronic alcohol intake, thereby exhibiting effects in preventing, improving, or treating alcoholic liver disease, as well as relieving hangovers.
- the present invention provides a pharmaceutical composition for preventing or treating alcoholic liver disease comprising an extract of Apios Americana tuber as an active ingredient; And it provides a health functional food composition for preventing or improving alcoholic liver disease.
- alcoholic liver disease means any liver disease resulting from alcoholic liver damage due to chronic alcohol intake.
- the alcoholic liver disease may be any one or more selected from the group consisting of alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis, but is not limited thereto.
- the present invention further provides a health functional food composition for relieving a hangover comprising an Apios Americana tuber extract as an active ingredient.
- the term “hangover” refers to a phenomenon in which discomfort, headache, or decline in mental and physical performance appear or persist after being intoxicated.
- Ethanol absorbed into the body due to drinking is mainly metabolized in the liver, oxidized to acetate via acetaldehyde, and then discharged out of the body. It is known that ALDH acts in the decomposition/oxidation process of
- ingested alcohol In the normal process of alcohol metabolism, ingested alcohol is absorbed in the stomach or small intestine, enters the bloodstream, and is transported to the liver. It can be decomposed into acetate and decomposed into carbon dioxide gas and water to be discharged out of the body.
- the Apios americana tuber extract according to the present invention increases the mRNA expression of ADH1 and ALDH2 in liver tissue reduced by alcohol
- Apios americana tuber extract A composition containing as an active ingredient increases the expression of ADH and / or ALDH mRNA in liver tissue to effectively remove hangover-causing substances, thereby reducing vomiting, nausea, dizziness, thirst, lethargy, headache, muscle pain, memory loss, heartburn, etc. It can improve hangover symptoms.
- prevention means any action to suppress or delay the onset of a disease or condition. In the present invention, it means delaying the onset of alcoholic liver disease or suppressing the onset of alcoholic liver disease.
- the term “improvement” refers to any action that improves or beneficially changes a disease or condition, and in the present invention means improving symptoms of alcoholic liver disease.
- treatment refers to any action that delays, stops, or reverses the progression of a disease or condition, and in the present invention, alleviates, alleviates, or reduces the symptoms of alcoholic liver disease. It means to remove or reverse.
- the present invention further provides a method for protecting alcoholic liver damage or relieving hangover and alcoholic liver disease, comprising administering an effective amount of Apios Americana tuber extract to a subject in need thereof. Preventive, ameliorative or therapeutic methods are provided.
- the present invention further provides use of an Apios Americana tuber extract in the preparation of a medicament or health functional food for protecting alcoholic liver damage or relieving hangover.
- the present invention further provides use of an Apios Americana tuber extract in the preparation of a medicament or nutraceutical for preventing, ameliorating or treating alcoholic liver disease.
- Apios americana tuber fraction may be administered for the purpose of protecting alcoholic liver damage, relieving hangover and/or preventing, improving or treating alcoholic liver disease.
- Apios americana tuber fraction may be included in drugs or health functional foods for protecting alcoholic liver damage or relieving hangover.
- Apios americana tuber fraction may be included in a pharmaceutical or health functional food for preventing, improving or treating alcoholic liver disease.
- a second aspect of the present invention relates to the use of an Apios americana tuber extract that exhibits a protective effect against alcoholic brain damage.
- the present invention provides a composition for protecting against alcoholic brain damage comprising Apios Americana tuber extract as an active ingredient.
- the description of the Apios americana tuber extract is the same as described above, so the description thereof is omitted.
- composition of the present invention may contain Apios americana tuber fraction as an active ingredient for use in protecting against alcoholic brain damage.
- composition according to the second aspect of the present invention since the description of the Apios americana tuber fraction is the same as described above, description thereof will be omitted.
- the present invention provides a pharmaceutical composition for preventing or treating alcoholic brain nervous system disease comprising an Apios Americana tuber extract as an active ingredient; And it provides a health functional food composition for preventing or improving alcoholic ventricular border disease.
- alcoholic brain nervous system disease includes all brain nervous system diseases that are directly induced by or indirectly related to alcohol intake, and the brain nervous system refers to the nervous system including the brain and spine. .
- alcoholic cranial nervous system diseases are specifically alcoholism, alcoholic amnesia, alcoholic dementia, alcoholic coma, Wernicke-Korsakoff syndrome, alcoholic neuropathy, and Marchiafavi-Binami disease.
- -It may be any one or more selected from the group consisting of Bignami disease (MBD), alcohol cerebellar degeneration, and central pontine myelinolysis (CPM), but is not limited thereto.
- the "alcoholism” indicates toxicity by suppressing various parts of the brain by alcohol, and various symptoms appear depending on the concentration of alcohol in the blood. At first, it is a stage of pleasure, such as inability to concentrate and talk a lot, and then there is an excitement stage, such as numbness and talk, and discordance in motor functions, such as memory loss, confusion, and disorientation.
- the "alcoholic amnesia” refers to a case in which a certain portion is not remembered partially (grayout) or completely (blackout) when drinking alcohol. It is related to the blood level of alcohol and can sometimes be confused with the passing out of alcohol, but it is characterized by the absence of loss of consciousness at all.
- the alcoholic amnesia can lead to alcoholic dementia. Dementia is a disease in which various cognitive functions, including memory, gradually develop, causing problems in the ability to perform daily life.
- the "alcoholic coma” is an internal medical emergency condition in which consciousness becomes blurred as the detoxification function of the liver is lowered and eventually loses consciousness.
- the "Wernicke-Korsakoff syndrome” is a continuation of Korsakoff's syndrome after Wernicke encephalopathy (WE), in which different stages of a disease appear consecutively.
- Wernicke's encephalopathy is an acute phase abnormal behavior syndrome characterized by eye movement disorders, mental state changes, and gait ataxia, and Korsakoff psychosis appears as Wernicke's encephalopathy improves.
- the "alcoholic neuropathy” is a neurological disease that is particularly common in patients with chronic alcohol addiction. Usually, when it starts slowly, sensory abnormalities appear, and pain or motor function abnormalities may accompany it.
- the "Marchiafava-Bignami disease (MBD)” is a kind of side effect caused by alcohol and is characterized by necrosis and atrophy of the corpus callosum. Clinically, it presents with speech difficulties, gait disturbance, disturbance of consciousness, convulsions, and disconnection syndrome with loss of corpus callosum.
- the "alcoholic cerebellar degeneration” refers to ataxia, wide gait, eye movement disorder due to nodular lobe damage, severe coordination disorder caused by lower extremities, and the like. There is degeneration of Purkinje cells, and white matter atrophy is evident in the central lobe and the anterior folia of the vermis.
- central pontine myelinolysis (CPM)
- CCM central pontine myelinolysis
- It is an acquired, symmetrical, non-inflammatory demyelinating disease of the base of the pons, which clinically results in decreased consciousness, dysphagia, dysarthria, ophthalmoplegia, facial paralysis, etc., and can develop into locked-in syndrome.
- the composition of the present invention is also effective in improving depression caused by alcohol.
- prevention refers to any action that suppresses or delays the onset of a disease or condition. In the present invention, it means delaying the onset of alcoholic brain nervous system disease or suppressing the onset of it.
- the term "improvement” refers to any action that improves or beneficially changes a disease or condition, and in the present invention, refers to improving symptoms of alcoholic cranial nerve disease. .
- treatment refers to any action that delays, stops, or reverses the progression of a disease or condition, and in the present invention, alleviates or alleviates the symptoms of alcoholic cranial nerve disease. or to eliminate, or to reverse.
- the present invention further provides a method for protecting alcoholic brain damage and prevention of alcoholic brain disease, comprising administering an effective amount of Apios Americana tuber extract to a subject in need thereof, Improvement or treatment methods are provided.
- the present invention further provides use of an Apios Americana tuber extract in the manufacture of a medicament or health functional food for protection against alcoholic brain damage.
- the present invention further provides the use of Apios Americana tuber extract in the manufacture of pharmaceuticals or health functional foods for the prevention, improvement or treatment of alcoholic brain diseases.
- Apios americana tuber fraction may be administered for the purpose of protecting alcoholic brain damage and/or preventing, improving or treating alcoholic liver disease.
- Apios americana tuber fraction may be included in drugs or health functional foods for protecting alcoholic brain damage or relieving hangover.
- Apios americana tuber fraction may be included in a drug or health functional food for preventing, improving or treating alcoholic brain disease.
- the pharmaceutical composition according to the present invention can be prepared into a pharmaceutical formulation using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- preparation of a dosage form it is preferable to mix or dilute the active ingredient with a carrier or to encapsulate it in a carrier in the form of a container.
- the pharmaceutical composition of the present invention is formulated according to conventional methods into oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions. It may further include appropriate carriers, excipients and diluents commonly used in the preparation of the composition.
- carriers that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose, etc. ) or by mixing lactose and gelatin.
- excipients for example, starch, calcium carbonate, sucrose, etc.
- lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, aromatics, preservatives, etc. may be included in addition to water and liquid paraffin, which are commonly used simple diluents. there is.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
- injectable esters such as ethyl oleate
- witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used as a base for the suppository.
- the term "administration" means introducing the pharmaceutical composition of the present invention to a patient by any suitable method.
- the administration method of the pharmaceutical composition according to the present invention is not particularly limited, and may follow a method commonly used in the art.
- the administration method is not limited as long as it can reach the target tissue, but may be intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, or intranasal administration.
- the pharmaceutical composition according to the present invention may be prepared in various formulations depending on the desired administration method.
- the pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount.
- the "pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is subject type and severity, age, sex, infected virus type, drug activity, drug sensitivity, time of administration, route of administration and excretion rate, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.
- a typical daily dose of the pharmaceutical composition according to the present invention can be appropriately selected by those skilled in the art, and can be administered once or divided into several times.
- composition of the present invention may be administered daily or intermittently, and the number of administrations per day may be administered once or divided into 2 to 3 times.
- composition of the present invention can be used alone or in combination with other drug treatments for the prevention, improvement, or treatment of alcoholic liver disease or brain nervous system disease. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all the above factors, and can be easily determined by those skilled in the art.
- the term "individual” refers to all animals, including humans, who have or are likely to develop alcoholic liver injury or alcoholic brain injury, more specifically, alcoholic liver disease or brain nervous system disease.
- the animal may be not only humans but also mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, and cats that require treatment for similar symptoms, but are not limited thereto.
- the term "food” refers to meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcohol Beverages, vitamin complexes, health functional foods and health foods, etc., include all foods in a conventional sense.
- the health functional food composition of the present invention includes forms such as pills, powders, granules, precipitates, tablets, capsules or liquids, and as foods to which the composition of the present invention can be added, for example, various foods, such as For example, there are beverages, chewing gum, tea, vitamin complexes, and health supplements.
- the food auxiliary additives include food auxiliary additives common in the art, such as flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like.
- natural carbohydrates examples include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavors eg, rebaudioside A, glycyrrhizin, etc.
- synthetic flavors sacharin, aspartame, etc.
- the health functional food composition of the present invention is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like.
- it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination.
- the health supplement includes health functional food and health food.
- the functional food is the same term as food for special health use (FoSHU), and is a medicine processed to efficiently display bioregulatory functions in addition to nutrient supply, and has high medical effect.
- “function (sex)” means to obtain useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions.
- the food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and ingredients commonly added in the art during the preparation.
- the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food.
- the health functional food composition of the present invention can be prepared in various types of formulations, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time using food as a raw material.
- the term "subject” includes any animal (eg, human, horse, pig, rabbit, dog, sheep, goat, non-human primate, cow, cat, guinea pig, or rodent), but It is not limited to this. These terms do not denote a specific age or gender. Thus, adult/adult and newborn subjects, whether female/female or male/male, as well as fetuses are intended to be included.
- a patient refers to a subject suffering from a disease or disorder. The term patient includes human and veterinary subjects.
- the effect of the Apios americana tuber extract or fraction and the composition including the route of administration, frequency of administration, dosage, etc. are the same as described above, so the description thereof will be omitted.
- Apios Americana tuber used in the present invention was purchased from a farm in Sacheon, Gyeongsangnam-do. After pulverizing the dried Apios tubers, they were extracted by immersion or ultrasonic extraction at about 40 °C using 10 to 15 times the weight of the sample in 70% ethanol solvent. If necessary, hot water extraction was performed at about 100 ° C using a reflux extraction device. Each extract was filtered, concentrated with a vacuum concentrator, and lyophilized to remove remaining solvent and water, and then the finished extract was homogenized.
- mice weighing 19 g or more were selected, and as shown in Table 1, they were divided into a normal control group, an ethanol-administered group, and a drug-administered group.
- the ethanol-treated group and the drug-treated group were fed a Lieber-DeCarli liquid diet containing 5% ethanol for 10 days to chronically consume alcohol, and the normal control group was fed the same diet without ethanol.
- the Apios americana extract prepared in Example 1 was orally administered to the drug administration group at a dose of 100 mg/kg and 200 mg/kg, respectively, at a fixed time every day.
- high-dose (5 g/kg) ethanol was orally administered to the ethanol-administered group and the drug-administered group, sacrificed 9 hours later, and blood and organs were obtained through autopsy.
- Relative weight of liver absolute weight of liver / body weight ⁇ 100
- the relative weight of the liver increased significantly in the alcohol-administered group compared to the normal control group, but the relative weight of the liver decreased in a concentration-dependent manner in the Apios extract-administered group.
- the Apios extract inhibits alcohol-induced fat deposition in liver tissue.
- the concentration of triglyceride (TG) in the blood increases, which increases the risk of fatty liver and circulatory diseases. Therefore, by measuring the TG concentration in the blood obtained from each group, the hepatoprotective effect of treatment with Apios extract was confirmed. As a result, as confirmed in 2, the TG concentration of the alcohol-administered group was significantly increased compared to the normal control group, but the increased TG concentration due to alcohol administration was significantly decreased in the Apios extract-administered group.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are enzymes that exist in liver cells and are released into the blood when liver cells are damaged, so the blood level increases. Liver function test is used as an indicator of Therefore, by measuring the levels of AST and ALT in the blood obtained from each group, the hepatoprotective effect of treatment with the Apios extract was confirmed. As a result, as confirmed in FIG. 3, the Apios extract reduced blood AST and ALT, which were increased due to alcohol, and showed statistically significant results when administered at 200 mg/kg.
- Alcohol dehydrogenases (ADH) and acetaldehyde dehydrogenases (ALDH) are enzymes that play the most important role in the process of metabolizing alcohol and acetaldehyde, which are cytotoxic substances.
- ADH and ALDH have several subclasses ( subclass), among which ADH1 and ALDH2 are the subclasses that play the most important roles, by measuring their mRNA expression levels, the liver protection effect and hangover relief effect according to Apios extract treatment were confirmed. As confirmed in 4, the Apios extract increased the mRNA expression of ADH1 and ALDH2 in the blood, which was reduced by alcohol, and showed statistically significant results when administered at 200 mg/kg.
- liver histological examination H&E staining was performed to observe the degree of fat deposition and inflammatory changes in the liver. As a result, as shown in FIG. 5, it was confirmed that fat deposition in the liver tissue was improved in the group administered with 100 mg/kg of Apios extract compared to the alcohol-administered group.
- mice of each group in Table 1 were evaluated for memory ability for fear situations experienced in a specific space.
- CFC behavioral tests were performed as shown in FIG. 6 . Specifically, after putting the mouse into the chamber during the training session and allowing it to move around freely for 120 seconds, an electric shock was applied to the foot through the grid. After 24 hours, mice were placed in the same chamber during the test period and behavioral patterns were evaluated. The higher the memory capacity for space, the lower the movement due to fear, so it was judged that the lower the ambulatory move time, the lower the cognitive impairment.
- the rotarod test was performed on the mice of each group in Table 1. As shown in Figure 6, 5 g / kg ethanol was orally administered on the morning of the 11th autopsy, and rotarod test was performed immediately before autopsy after 9 hours. First, after adapting the mouse for 30 seconds at a speed of 5 rpm in a rotating cylinder, the time until it fell from the cylinder to the floor was measured while increasing the speed from 5 rpm to 40 rpm for 300 seconds. The better the sense of balance and motor coordination, the longer the latency time to fail, so it was judged that the longer the latency time to fail, the more effective the cognitive impairment was.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La présente invention se rapporte à une utilisation d'un extrait de tubercule d'Apios americana pour une protection contre une lésion hépatique alcoolique ou une lésion cérébrale alcoolique, et plus particulièrement, fournit une composition destinée à la protection contre une lésion hépatique alcoolique ou une lésion cérébrale alcoolique et se rapporte à une méthode de protection contre une lésion hépatique alcoolique ou une lésion cérébrale alcoolique, chacune utilisant un extrait de tubercule d'Apios americana. En outre, la présente invention concerne une composition destinée à la prévention, au soulagement ou au traitement d'une maladie hépatique alcoolique ou d'une maladie du système nerveux cérébral et une méthode destinée à la prévention, au soulagement ou au traitement d'une maladie hépatique alcoolique ou d'une maladie du système nerveux cérébral, chacune utilisant un extrait de tubercule d'Apios americana. En outre, la présente invention concerne une composition destinée à soulager la gueule de bois et une méthode destinée à soulager la gueule de bois, chacune utilisant un extrait de tubercule d'Apios americana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210184374A KR20230094888A (ko) | 2021-12-21 | 2021-12-21 | 아피오스 아메리카나 괴경 추출물을 포함하는 알코올성 간 손상 또는 알코올 뇌 손상 보호용 조성물 |
KR10-2021-0184374 | 2021-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023121314A1 true WO2023121314A1 (fr) | 2023-06-29 |
Family
ID=86903098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/020995 WO2023121314A1 (fr) | 2021-12-21 | 2022-12-21 | Utilisation d'un extrait de tubercule d'apios americana pour une protection contre une lésion hépatique alcoolique ou une lésion cérébrale alcoolique |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20230094888A (fr) |
WO (1) | WO2023121314A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011037800A (ja) * | 2009-08-18 | 2011-02-24 | Aomori Univ Of Health & Welfare | アピオス花を用いた血糖値上昇抑制物質および糖尿病予防用食品素材 |
CN107582562A (zh) * | 2017-08-28 | 2018-01-16 | 浙江大学 | 豆芋花多糖在降低肝细胞脂质沉积中的应用 |
KR20190020889A (ko) * | 2017-08-22 | 2019-03-05 | 안동대학교 산학협력단 | 아피오스 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
KR20200145757A (ko) * | 2019-06-19 | 2020-12-30 | 한국 한의학 연구원 | 아피오스 아메리카나 괴경 추출물의 분획물을 포함하는 알코올성 위염 예방, 개선 또는 치료용 조성물 및 이의 제조방법 |
-
2021
- 2021-12-21 KR KR1020210184374A patent/KR20230094888A/ko not_active Application Discontinuation
-
2022
- 2022-12-21 WO PCT/KR2022/020995 patent/WO2023121314A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011037800A (ja) * | 2009-08-18 | 2011-02-24 | Aomori Univ Of Health & Welfare | アピオス花を用いた血糖値上昇抑制物質および糖尿病予防用食品素材 |
KR20190020889A (ko) * | 2017-08-22 | 2019-03-05 | 안동대학교 산학협력단 | 아피오스 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
CN107582562A (zh) * | 2017-08-28 | 2018-01-16 | 浙江大学 | 豆芋花多糖在降低肝细胞脂质沉积中的应用 |
KR20200145757A (ko) * | 2019-06-19 | 2020-12-30 | 한국 한의학 연구원 | 아피오스 아메리카나 괴경 추출물의 분획물을 포함하는 알코올성 위염 예방, 개선 또는 치료용 조성물 및 이의 제조방법 |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "A Study on Materials for Improving Alcoholic Liver Disease Using Apios", RESEARCH REPORT, 31 December 2021 (2021-12-31), pages 1 - 54, XP009554414 * |
HYO-YOUNG KIM, JANG KIM, YANGKANG SO, SI-YONG KANG, HYE JEONG, CHANG JIN: "Anti-Inflammatory Effect of Lupinalbin A Isolated from Apios americana on Lipopolysaccharide-Treated RAW264.7 Cells", MOLECULES, vol. 23, no. 3, 1 January 2018 (2018-01-01), pages 583, XP055767230, DOI: 10.3390/molecules23030583 * |
Also Published As
Publication number | Publication date |
---|---|
KR20230094888A (ko) | 2023-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018012834A1 (fr) | Souche d'akkermansia muciniphila présentant un effet de prévention ou de traitement de maladies dégénératives du cerveau ou de maladies métaboliques et utilisation correspondante | |
WO2014171781A1 (fr) | Composition prévenant ou traitant les symptômes de la xylostomiase | |
WO2019199094A1 (fr) | Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante | |
WO2015002391A1 (fr) | Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles | |
WO2016060426A1 (fr) | Composition contenant un extrait de dolichos lablab l. comme principe actif pour prévenir ou soulager une stéatose hépatique non alcoolique | |
WO2018124708A1 (fr) | Composition pour prévenir ou soulager la gueule de bois, contenant un extrait de longan arillus | |
WO2016032249A1 (fr) | Composition pharmaceutique contenant un extrait de vaccinium bracteatum thunb. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives | |
WO2022145893A1 (fr) | Composition permettant de soulager le stress comprenant du noni et du calamondin fermentés et vieillis comme principes actifs | |
WO2017183902A1 (fr) | Composition contenant des extraits de artemisia capillaris, sanguisorba officinalis et curcuma longa et un agent antiviral, en tant que principes actifs, destinée à prévenir ou traiter une maladie du foie | |
WO2016190566A2 (fr) | Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif | |
WO2024048934A1 (fr) | Nouvelle bactérie lactique lactiplantibacillus plantarum sko-001 pour réduire la graisse corporelle, et ses utilisations | |
WO2020256464A1 (fr) | Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production | |
WO2018093237A2 (fr) | Composition comprenant de l'acide formique ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif pour la prévention ou le traitement de l'obésité ou des syndromes métaboliques provoqués par l'obésité | |
WO2014196775A1 (fr) | Souche de lactobacillus brevis g-101 et son utilisation | |
WO2017099509A1 (fr) | Composition pour le traitement ou la prévention de maladies du foie contenant comme principe actif un extrait de sicyos angulatus | |
WO2016093613A2 (fr) | Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma | |
WO2015167240A1 (fr) | Composition contenant un extrait de scutellaria alpina | |
WO2023106777A1 (fr) | Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci | |
WO2023121314A1 (fr) | Utilisation d'un extrait de tubercule d'apios americana pour une protection contre une lésion hépatique alcoolique ou une lésion cérébrale alcoolique | |
WO2019212300A1 (fr) | Composition comprenant un extrait d'aster koraiensis nakai ou une fraction de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie de parkinson | |
WO2016117762A1 (fr) | Composition contenant un extrait de groseille à maquereau ou du glutathion | |
WO2021080298A1 (fr) | Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière | |
WO2018030650A1 (fr) | Composition anti-obésité contenant un extrait de feuilles de chrysanthème en tant que principe actif | |
WO2015152653A1 (fr) | Composition comprenant un extrait de feuilles de génépi blanc | |
WO2012105816A2 (fr) | Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22911947 Country of ref document: EP Kind code of ref document: A1 |